SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sarepta Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$17.73+0.63 (+3.68%)
Close on Oct 19, 2026
- Market cap
- $1.87B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.78 (−21.24%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Sarepta Therapeutics, Inc. saw revenue fall 20.4% to $1.97B over the twelve months to Jun 30, 2026. Free cash flow was $81.85M.
Revenue
$1.97B
-20.4% vs. a year earlier
Operating income
-$143.25M
TTM Q2 2026
Free cash flow
$81.85M
TTM Q2 2026
EPS, diluted
-$1.60
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.87B
- P/E ratio
- –
- Price to sales
- 0.95
- Price to book
- 1.22
- Dividend yield
- –
- Free cash flow yield
- 4.38%
Fundamentals
- Revenue
- $1.97B
- Net income
- -$136.73M
- EPS, diluted
- -$1.60
- Free cash flow
- $81.85M
- Book value per share
- $14.49
- Diluted shares
- 105M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$1.97B-20.4% YoY
Gross profit
–
Operating income
-$143.25M
Net income
-$136.73M
EPS, diluted
-$1.60
Free cash flow
$81.85M
Reported periodTrailing twelve months